NCT00003514 2013-07-10Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyNational Cancer Institute (NCI)Phase 2 Withdrawn